Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II

Molecular Genetics and Metabolism Reports

Volumn 2, Issue , 2015, Pages 20-24

  Kim, Katherine H ^a   Messinger, Yoav H ^b   Burton, Barbara K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Children's Hospitals   (United States)

Author keywords

Anti idursulfase antibody titer; Enzyme replacement therapy; Immune modulation; MPS II; Treatment

Indexed keywords

BORTEZOMIB; CREATININE; DEXAMETHASONE; ENZYME ANTIBODY; GLYCOSAMINOGLYCAN; HYMECROMONE SULFATE; IDURONATE 2 SULFATASE; IDURONATE 2 SULFATASE ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METHOTREXATE; NEUTRALIZING ANTIBODY; OFATUMUMAB; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CASE REPORT; CHILD; CREATININE URINE LEVEL; DRUG DOSE INCREASE; ENZYME ACTIVITY; ENZYME REPLACEMENT; GENE DELETION; HUMAN; HUNTER SYNDROME; IMMUNOMODULATION; LIVER SIZE; MAINTENANCE THERAPY; MALE; PRESCHOOL CHILD; URINARY EXCRETION;

EID: 84923225602     PISSN: None     EISSN: 22144269     Source Type: Journal    
DOI: 10.1016/j.ymgmr.2014.11.007     Document Type: Article

References (22)

1. J. Nelson Incidence of the mucopolysaccharidoses in Northern Ireland Hum. Genet. 101 1997 335 358
2. B.J.H.M. Poorthius, R.A. Wevers, and W.J. Kleijer The frequency of lysosomal storage diseases in The Netherlands Hum. Genet. 105 1999 151 156
3. J. Nelson, J. Crowhurst, B. Carey, and L. Greed Incidence of the mucopolysaccharidoses in Western Australia Am. J. Med. Genet. 123A 2003 310 313
4. F. Baehner, C. Schmiedeskamp, and F. Krummenauer Cumulative incidence rates of the mucopolysaccharidoses in Germany J. Inherit. Metab. Dis. 28 2005 1011 1017
5. I.D. YoungS. Harper, I.M. Archer, and R.G. Newcombe A clinical and genetic study of Hunter's syndrome. 1 Heterogeneity J. Med. Genet. 19 1982 401 407
6. I.V.D. Schwartz, M.G. Ribeiro, and J.G. Mota A clinical study of 77 patients with mucopolysaccharidosis type II Acta Paediatr. 96 2007 63 70
7. R. Martin, M. Beck, and C. Eng Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome) Pediatrics 121 2008 e377 e3386
8. M.G. Matheus, M. Castillo, and J.K. Smith Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation Neuroradiology 46 2004 666 672
9. R. Froissart, I. Moreira Da Silva, and I. Maire Mucopolysaccharidosis type II: an update on mutation spectrum Acta Paediatr. 96 2007 71 77
10. J. Muenzer, J.E. Wraith, and M. Beck A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) Genet Med. 8 2006 465 473
11. J. Muenzer, M. Beck, and C. Eng Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome Genet Med. 13 2011 95 101
12. N.J. Mendelsohn, Y.H. Messinger, A.S. Rosenberg, and P.S. Kishnani Elimination of antibodies to recombinant enzyme in Pompe's disease N. Engl. J. Med. 360 2009 194 195
13. P.S. KishnaniC. Goldenberg, and S.L. DeArmey Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants Mol. Genet. Metab. 99 2010 26 33
14. Y.H. Messinger, N.J. Mendelsohn, and W. Rhead Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease Genet Med. 14 2012 135 142
15. A.J. Barbier, B. Bielefeld, and S.A.H. Whiteman The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase Mol. Genet. Metab. 110 2013 303 310
16. J.G.N. De Jong, R.A. Wevers, and R. Liebrand van Sambeek Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue Clin. Chem. 38 1992 803 807
17. J.E. Stone, N. Akhtar, S. Botchway, and C.A. Pennock Interaction of 1,9-dimethylmethylene blue with glycosaminoglycans Ann. Clin. Biochem. 31 1994 147 152
18. S.G. Banugaria, S.N. Prater, and J.K. McGann Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease Genet Med. 15 2013 123 131
19. T. van Meertena, and A. Hagenbeekb CD20-targeted therapy: the next generation of antibodies Semin. Hematol. 47 2010 199 210
20. M. Ostergaard, B. Baslund, and W. Rigby Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study Arthritis Rheum. 62 2010 2227 2238
21. P. Kapoor, V. Ramakrishnan, and S.V. Rajkumar Bortezomib combination therapy in multiple myeloma Semin. Hematol. 49 2012 228-142
22. R. Tomanin, A. Zanetti, and F. D'Avanzo Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years Orphanet J. Rare Dis. 9 2014 1 16